Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Eur J Rheumatol. 2017 Mar;4(1):29-35. doi: 10.5152/eurjrheum.2017.16059. Epub 2017 Mar 1.

IL-17A levels in systemic lupus erythematosus associated with inflammatory markers and lower rates of malignancy and heart damage: Evidence for a dual role.

Author information

1
Rheumatology Group, The University of Western Australia School of Medicine, Crawley, Western Australia.
2
Department of Clinical Medicine, Bone & Joint Group, Arctic University, Tromsø, Norway.
3
Rheumatology Group, The University of Western Australia School of Medicine, Crawley, Western Australia; Department of Clinical Medicine, Bone & Joint Group, Arctic University, Tromsø, Norway; Department of Rheumatology, Sir Charles Gairdner Hospital, Nedlands, Western Australia.

Abstract

OBJECTIVE:

The interleukin 17 (IL-17) cytokine family is involved in a number of chronic inflammatory diseases. In spite of contradictory findings and a lack of causality in clinical studies, IL-17 inhibition for systemic lupus erythematosus (SLE) has regained attention as a potential therapeutic pathway, after demonstrating disease-modifying capabilities in ankylosing spondylitis. We investigated the clinical associations of interleukin 17 A (IL-17A) in patients with SLE.

MATERIAL AND METHODS:

A cross-sectional study was performed involving SLE patients (n=102; age: 49 years; 86% female) recruited from a regional registry. IL-17A levels were determined by immunoassay, disease activity by Systemic Lupus Erythematosus Disease Activity Index-2K (SLEDAI-2K), and cumulative damage by Systemic Lupus International Collaborative Clinics Damage Index (SDI) scores. Non-parametric techniques were used to examine the association between IL-17A and disease activity and autoantibody profiles were compared with healthy controls (n=31): principal component analysis (PCA) was used to determine the interplay of immune cells across disease states and damage development in SLE patients.

RESULTS:

SLE patients had higher IgG levels, lower T-cell and B-cell counts, but median IL-17A levels did not differ from the controls (28.4 vs. 28.4 pg/mL, p=0.9). In SLE patients, IL-17A did not correlate with SLEDAI-2K or SDI, but was inversely related with age (correlation coefficients, Rs.=-0.29, p<0.05), systolic blood pressure (Rs.=-0.31, p<0.05), years of smoking (Rs.=-0.43, p<0.05), cumulative heart (Rs.=-0.22, p<0.05), and malignancy damage (Rs.=-0.18, p<0.05). Serological correlations for IL-17A existed with immunoglobulin G (IgG) levels (Rs.=0.21, p<0.05), high sensitivity C-reactive protein (hs-CRP) levels (Rs.=0.28, p<0.05), proteinuria (Rs.=0.64, p<0.05), and pre-albumin (Rs.=-0.22, p<0.05). Longitudinal data showed only modest fluctuation in IL-17A levels, independent of SLEDAI-2K.

CONCLUSION:

These results suggest that IL-17A, while participating in inflammation, may also serve a protective purpose in SLE patients.

KEYWORDS:

IL-17A; SLEDAI; Systemic Lupus Erythematosus; organ damage

Conflict of interest statement

Conflict of Interest: No conflict of interest was declared by the authors.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center